Overview

Photodynamic Therapy in Occult-Only Lesions (POOL)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
QLT Inc.
Treatments:
Verteporfin